ArticleHaematologica2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Selective activation of STAT3 and STAT5 dictates the fate of myeloid progenitor cells.Cell death discovery · 2023Article
- HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway.Human cell · 2023Article
- Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia.Journal of cell communication and signaling · 2022Article
- Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.Pharmaceutical biology · 2021Article
- A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.Cells · 2021Review
- The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.Biomedicines · 2021Review
- Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.Frontiers in oncology · 2021Review
- The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.Haematologica · 2021Article
- 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.Cancers · 2020Review
- [Mechanism of STAT3 phosphorylation mediated leukemia cells resistance to doxorubicin].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol inCancers · 2019Article
- Review
- Balancing STAT Activity as a Therapeutic Strategy.Cancers · 2019Review
- Article
- A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions.Cancers · 2019Article
- Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein.Neoplasia (New York, N.Y.) · 2019Article
- Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.Cell stem cell · 2019Article
- A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1Leukemia research · 2019Article
- Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells.Cell & bioscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Karoline V GleixnerDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria karoline.gleixner@meduniwien.ac.at.
Mathias SchneeweissLudwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
Gregor EisenwortLudwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
Daniela BergerDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
Harald HerrmannLudwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
Katharina BlattDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
Georg GreinerDepartment of Laboratory Medicine, Medical University of Vienna, Austria.
Konstantin ByrgazovChildren's Cancer Research Institute (CCRI), Vienna, Austria.
Gregor HoermannLudwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
Marina KonoplevaDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Islam WaliulInstitute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
Abbarna A CumaraswamyDepartment of Chemistry, University of Toronto, Canada.
Patrick T GunningDepartment of Chemistry, University of Toronto, Canada.
Hiroshi MaedaInstitute of Drug Delivery Sciences, Sojo University, Kumamoto and BioDynamics Research Laboratory, Kumamoto, Japan.
Richard MorigglLudwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Michael DeiningerDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Thomas LionChildren's Cancer Research Institute (CCRI), Vienna, Austria.
Michael AndreeffDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.
Medical University of Vienna · ATLudwig Boltzmann Cluster for Cardiovascular Research · ATSojo University · JPThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CALudwig Boltzmann Institute for Cancer Research · ATUniversity of Utah · US
Funding
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemiaR01CA178397 · NCI · UNIVERSITY OF UTAH · PI DEININGER, MICHAEL W., O'HARE, THOMAS J. · 2014 to 2018
$2.6MNCI NIH HHS R01 CA178397
Abstract
In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of
Indexed as
Drug Delivery SystemsAdultAgedAged, 80 and overCell Line, TumorDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplastic Stem CellsProtein Kinase InhibitorsSTAT3 Transcription FactorSTAT5 Transcription FactorBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablProtein Kinase InhibitorsSTAT3 protein, humanSTAT3 Transcription FactorSTAT5 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.